Stem Cell Therapy for Diabetic Retinopathy

Diabetic retinopathy (DR) — damage to the retina's blood vessels caused by chronically high blood sugar — is a leading cause of vision loss in working-age adults. Stem cell approaches, mainly mesenchymal stem cells (MSCs) from bone marrow, fat, or umbilical cord tissue, are being studied for their potential to protect retinal blood vessels and calm the inflammation that drives DR. No stem cell product is FDA-approved for this condition. Evidence in humans is limited to one small pilot trial and a scattering of early-phase and preclinical studies, while standard treatments — anti-VEGF injections, laser photocoagulation, and blood sugar control — remain the proven options.

Overview

Diabetic retinopathy develops when years of elevated blood glucose damage the small blood vessels feeding the retina, causing leakage, abnormal new vessel growth, and eventually vision-threatening complications like macular edema or retinal detachment. It's distinct from other retinal diseases the site covers separately, such as age-related macular degeneration or retinitis pigmentosa, though researchers sometimes study overlapping cell therapies across these conditions. Current standard care — anti-VEGF drugs, laser treatment, and tight glycemic control — can slow or stabilize DR but doesn't reverse existing vessel damage, which is why regenerative approaches have drawn research interest.

How It's Thought to Work

Most investigational stem cell approaches use MSCs, delivered either intravenously or, more rarely, directly into the eye. Preclinically, MSCs and their secreted factors (exosomes, growth factors) are thought to reduce oxidative stress and inflammation in the retina, support the blood-retinal barrier, and in some models promote repair of damaged capillaries. Other lines of research are exploring induced pluripotent stem cell (iPSC)-derived vascular cells aimed at repairing degenerated retinal vessels directly. Almost all of this mechanistic work so far comes from cell-culture and animal studies rather than humans.

What the Evidence Shows

The most substantive human data comes from a small, non-randomized, open-label pilot trial published in Cellular Physiology and Biochemistry (2018), which gave 17 people with type 2 diabetes and DR (34 eyes total) a single intravenous infusion of their own expanded bone marrow MSCs. In participants with severe non-proliferative DR (the earlier stage), best-corrected visual acuity improved significantly at 3 months (P = 0.006) and remained significantly improved at 6 months (P = 0.027), alongside macular thickness reductions, with no severe adverse events, immune rejection, or infusion-related reactions reported. Notably, the same infusion produced no significant visual acuity change in participants with more advanced, non-high-risk proliferative DR, leading the authors to suggest the optimum therapeutic window may be earlier in the disease. A 2025 review in the Journal of Clinical Medicine surveys this and related mechanistic work and concludes the field remains largely preclinical overall, while flagging that unregulated stem cell clinics offering unproven injections for retinal disease have caused serious harm, including permanent vision loss, in some patients — a warning echoed across the ophthalmology literature. A registered study, ClinicalTrials.gov NCT03403699, is testing iPSC-derived cells intended to repair damaged retinal vessels in DR, showing research is continuing, but no large or controlled human trial results are yet available.

Who Might Be a Candidate

• People with diabetic retinopathy should not consider stem cell therapy a substitute for anti-VEGF injections, laser treatment, or glycemic control — these remain the only treatments with strong evidence behind them.
• The only people who have received investigational stem cell infusions for DR did so inside a monitored clinical trial, with lab-processed, quality-tested cells and standardized dosing — a very different situation from a direct-to-consumer stem cell clinic.
• Anyone considering enrolling in research should look specifically for a listing on ClinicalTrials.gov, verify oversight by an institutional review board, and discuss it with their treating ophthalmologist and endocrinologist first.
• Patients with advanced proliferative DR should be especially cautious, since the one available pilot trial found little benefit — and unregulated clinics report the worst outcomes — at this later stage.

Bottom Line

There is a real, if early, scientific case for stem cell approaches in diabetic retinopathy: a small pilot trial found meaningful, statistically significant visual acuity improvements with a good safety profile in earlier-stage disease, and mechanistic research continues to build a case for how MSCs might protect retinal vessels. But this is one small, non-randomized study — not proof the therapy works — and no stem cell treatment is FDA-approved for DR. Standard care (anti-VEGF therapy, laser treatment, and blood sugar management) remains the evidence-backed foundation of treatment, and patients should be wary of any clinic offering stem cell injections for DR outside a registered clinical trial.